Engineered Tregs to Designed to Overcome Therapeutic Bottlenecks for Achieving Therapeutic Benefit in Type 1 Diabetes
Time: 1:30 pm
day: Day One Track A, PM
Details:
• Discussing the advantages of GNT-122, including a targeted, stable phenotype with a chemically inducible signaling complex (CISC) to overcome the IL-2 scarce environment in T1D
• Highlighting the importance of Tregs in regulating acute inflammatory responses
